Introduction {#s1}
============

Receptor tyrosine kinases (RTKs) form multiprotein complexes at the cell membrane that mediate signal initiation and propagation, as well as feedback control mechanisms ([@bib25]). While cell-free activity profiling may only uncover chemicals that directly target RTK catalytic function, in-cell profiling confers several additional benefits that could improve the drug development process. First, RTKs are targeted in their natural conformation, with post-translational modifications and in the cell metabolic environment. The protein-protein interactions involved in signal transduction through the RTK-associated signaling complexes, downstream elements, or effector pathways may also be targeted, increasing the chance of success. In-cell profiling may identify biological pathways that naturally oppose the signaling of a certain RTK, and can then be therapeutically exploited ([@bib38]). Furthermore, this approach may also enable the targeting of RTKs in non-signaling states, via interference either with their expression, maturation and transport to the cell membrane or their internalization and degradation. Finally, in-cell activity profiling is applicable to disease-specific in vitro and in vivo models. This is important in the development of therapeutics for chronic diseases caused by pathological RTK signaling, such as diabetes, pulmonary hypertension, chronic kidney disease, or developmental disorders ([@bib11]; [@bib35]; [@bib13]; [@bib24]), all of which are poorly represented in current clinic ([@bib2]). Lastly, several important oncogenes and downstream targets of RTK signaling, such as RAS, appear not druggable directly ([@bib6]) and thus the inhibitors of their signaling may only be discovered via in-cell activity profiling. However, the existing toolkits for in-cell RTK activity profiling provide only partial solutions for the development of RTK inhibitors, as they only focus on a few RTKs or their disease-associated mutants ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}), are technically or instrumentally challenging, or require the development of RTK-specific tools ([@bib30]; [@bib16]; [@bib33]).

A majority of known RTKs activate the RAS/RAF/MEK/ERK MAP kinase signaling module, a pathway that links extracellular mitogenic signals to gene transcription ([@bib36]; [@bib27]). Hence, the strong effect of ERK on gene transcription could be exploited in the development of reporters that are applicable to the activity profiling of many different RTKs ([@bib39]). Here, we report the engineering of one such system, which is based on the promoter sequences of the ERK target gene *EGR1* (*Early growth response 1*). We demonstrate that the *EGR1*-based reporter system is applicable to simple in-cell activity profiling of most protein kinase oncogenes. Additionally, we generate proof-of-concept examples for the use of this system in the identification of novel targets for clinically used protein kinase inhibitors.

Results and discussion {#s2}
======================

Exploitation of the *EGR1* for the activity profiling of fibroblast growth factor receptor (FGFR) {#s2-1}
-------------------------------------------------------------------------------------------------

We focused on the particularly strong ERK activation triggered by FGFR signaling in multiple myeloma and [r]{.ul}at [c]{.ul}hondro[s]{.ul}arcoma (RCS) cells to identify genes which are upregulated upon ERK activation. The expression profiling of cells treated with FGFR ligand FGF2 identified *Egr1*, *Egr2*, *Nr4A2*, *Dusp6* and *Rgs1* among the most strongly induced genes ([@bib19]; [@bib3]). The putative promoter sequences of human *EGR1*, *EGR2*, *NR4A2*, *DUSP6* and *RGS1,* located directly upstream of the transcription start sites ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}), were cloned into the promoterless pGL4.17 vector carrying firefly luciferase. In dual-luciferase activity assays performed in RCS cells, *EGR1* promoter showed the strongest response, as it was *trans*-activated approximately 12-fold following FGF2 treatment ([Figure 1A](#fig1){ref-type="fig"}), and was therefore chosen for subsequent studies. FGF2 induced endogenous EGR1 protein expression in seven different cell types tested, and this phenotype was dependent on ERK activation ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).10.7554/eLife.21536.002Figure 1.Development of luciferase and fluorescent reporters based on a human *EGR1* promoter.(**A**) The activity of various reporters, based on promoters of FGF2-responsive genes, cloned into a pGL4.17 vector expressing firefly luciferase. The FGF2-mediated *trans*-activation (fold-change compared to unstimulated cells) of these reporters in RCS cells was determined by the dual-luciferase assay. Insert, induction of EGR1 protein expression in RCS cells treated with FGF2. (**B**--**E**) Four consecutive rounds of *EGR1* promoter sequence optimization leading to the pKrox24(2xD-E_inD)^Luc^ reporter, including 5'-prime shortening (**B**,**C**), 3'-prime shortening (**D**), and addition of repetitive D-elements (**E**) to the originally cloned *EGR1* promoter (vectors outlined in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The presented data were generated through dual-luciferase assays in RCS cells, with 'n' describing the number of independent experiments. Statistically significant differences are highlighted (Student´s t-test; \*\*p\<0.01, \*\*\*p\<0.001). (**F**, **G**) FGF2-mediated induction of dTomato protein expression (**F**) and fluorescence (**G**) in RCS cells transiently transfected with pKrox24(2xD-E)^dTomato^ or pKrox24(MapErk)^dTomato^ reporters. Bar, 150 µm. (**H**) Transactivation of pKrox24(2xD-E)^dTomato^ in RCS cells induced by forced expression of the constitutively active FGFR3 K650M mutant, determined by live cell imaging of dTomato fluorescence over 24 hr. The dTomato induction was suppressed by the FGFR inhibitor AZD1480. (**I**) Immunoblot validation of DsRed induction and ERK phosphorylation (p) in RCS cells transfected with FGFR3 K650M mutant together with pKrox24(2xD-E)^DsRed^ for 16 hr. Actin and total ERK levels served as loading controls.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.002](10.7554/eLife.21536.002)10.7554/eLife.21536.003Figure 1---figure supplement 1.FGF2 induces EGR1 expression dependent on ERK MAP kinase.(**A**) Immunoblot analysis of EGR1 protein induction in cultured cells treated with FGFR ligand FGF2 (40 ng/ml in hESC, hiPSC and NIH3T3; 10 ng/ml +1 µg/ml heparin in 293T, LP1 and KMS11 cells) for indicated times. hESC, human embryonic stem cells; hiPSC, human induced pluripotent stem cells; NIH3T3, mouse embryonal fibroblasts; 293T, human embryonal kidney cells; LP1, KMS11 human multiple myeloma cell lines. Actin serves as the loading control. (**B**) RCS cells were treated with ERK MAP kinase pathway inhibitor PD0325901 for 30 min prior FGF2 addition, and analyzed for ERK activating phosphorylation (pERK) and EGR1 induction one hour later. EGR1 induction by FGF2 depends on ERK activity. Actin and total ERK levels serve as loading controls. Data show representative experiment for three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.003](10.7554/eLife.21536.003)10.7554/eLife.21536.004Figure 1---figure supplement 2.Schematic outline of human *EGR1* promoter sequences cloned into the promoterless pGL4.17 vector carrying firefly luciferase, and analyzed for FGF2-mediated *trans*-activation as shown by [Figure 1A--E](#fig1){ref-type="fig"}.The variants generated during four rounds of experimental optimization are indicated. TSS, transcription start site.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.004](10.7554/eLife.21536.004)10.7554/eLife.21536.005Figure 1---figure supplement 3.Analysis workflow of the dual-luciferase assay.Cells were transfected with promoterless pGL4.17 vector expressing firefly luciferase or containing cloned *EGR1* promoter (pGL4.17-EGR1-D), together with vector carrying *Renilla* luciferase under constant promoter (pRL-TK) (transfection control). Chemiluminescence signals generated by each luciferase were determined by dual-luciferase assay (left graph; n = 8, four biological replicates each measured twice) and used to calculate F-luc/*R*-luc ratios for control and FGF2-treated cells (middle graph). These ratios were used to calculate a fold difference in pGL4.17-EGR1-D *trans*-activation between untreated and FGF2-stimulated cells (right graph).**DOI:** [http://dx.doi.org/10.7554/eLife.21536.005](10.7554/eLife.21536.005)10.7554/eLife.21536.006Figure 1---figure supplement 4.The extent of pKrox24(2xD-E_inD)^Luc^ reporter *trans*-activation with increasing FGF2 concentrations in RCS cells.Data are generated by dual-luciferase assay and represent an average from indicated number of independent experiments (n) with SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.006](10.7554/eLife.21536.006)10.7554/eLife.21536.007Figure 1---figure supplement 5.Validation of pKrox24(2xD-E_inD)^Luc^ reporter in cellular models to FGFR signaling.(**A**) Cultured 293T and NIH3T3 cells were transfected with pKrox24(2xD-E_inD)^Luc^, treated with FGF2 24 hr later and analyzed by luciferase assay after 20 hr. FGF2 *trans*-activated pKrox24(2xD-E_inD)^Luc^ in both cell types. (**B**) hESC, hiPSC and KMS11 cells were transfected similar to (**A**) and endogenous high levels of FGF signaling were inhibited by small chemical inhibitors of FGFR catalytic activity AZD1480 (2 µM) and BGJ398 (10, 20, 40, 100 nM). Statistically significant differences are indicated (Student´s t-test; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). n, number of independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.007](10.7554/eLife.21536.007)10.7554/eLife.21536.008Figure 1---figure supplement 6.Generation of pKrox24(MapErk) reporters.Conserved transcription factor binding sites were mapped to human *EGR1* promoter together with information obtained during development of pKrox24(2xD-E_inD) reporters. A region crucial for the activity of the reporter overlapped with evolutionary conserved element (yellow box) and thus it was analyzed for transcription factors binding sites. Selected transcription factor responsive elements were then used for construction of the synthetic reporter where binding sites (BS) for SP1, CREB1, ELK1, ELK4, SRF and EGR1 itself were cloned five times in a row into pGL4.26 vector. TSS, transcription start site.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.008](10.7554/eLife.21536.008)10.7554/eLife.21536.009Figure 1---figure supplement 7.Comparison of transactivation capacity and basal activity of pKrox24(MapErk)and pKrox24(2xD-E_inD) reporters.(**A**) Comparison of FGF2-mediated *trans*-activation pKrox24(2xD-E_inD)^Luc^, pKrox24(MapErk)^Luc^ and pGL4.17-EGR1-D reporters in RCS cells. Statistically significant differences are indicated (Student´s t-test; \*p\<0.05, \*\*p\<0.01). (**B**) Determination of basal levels of pKrox24(2xD-E_inD)^Luc^ and pKrox24(MapErk)^Luc^ activity in untreated 293T and RCS cells, transfected with indicated vectors for 24 hr, parental vectors are also shown. Data generated by dual-luciferase assay. n, number of independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.009](10.7554/eLife.21536.009)10.7554/eLife.21536.010Figure 1---figure supplement 8.FGF-mediated transactivation of constructs containing D-E or MapErk promoter elements combined with dTomato or DsRed reporters.(**A**) RCS cells were transfected with pCLuc-Basic2 vector expressing dTomato under the pKrox24(2xD-E) promoter and treated with FGF2 (50 ng/ml) for 24 hr. dTomato expression was monitored by automatic incubation microscope BioStation CT (Nikon) over the entire 24 hr period of time and plotted (**B**) against signal recorded in FGF2-naïve cells transfected with pKrox24(2xD-E)^dTomato^. Scale bar 150 µm. (**C**) RCS cells were transiently transfected with activating FGFR3 mutant K650M together with pKrox24(2xD-E)^dTomato^ vector for 24 hr alone or in the presence of FGFR inhibitor AZD1480. Representative images at 24 hr were acquired using confocal microscope Carl Zeiss LSM 700. Bar, 150 µm. dTomato fluorescence was recorded by BioStation CT over the entire 24 hr period of time, data are graphed and presented at [Figure 1H](#fig1){ref-type="fig"}. (**D**) Immunoblot analysis of dTomato and DsRed induction in FGF2-treated RCS cells transfected with vectors expressing DsRed and dTomato under the control of both pKrox24(2xD-E) and pKrox24(MapErk) promoters. Controls are non-transfected cells or those transfected with empty plasmid. Actin serves as the loading control. Numbers of independent experiments (n): 4 (**A**), 4 (**B**), 3 (**C**), 3 (**D**).**DOI:** [http://dx.doi.org/10.7554/eLife.21536.010](10.7554/eLife.21536.010)

To identify FGF2-responsive elements, we generated 13 truncated variants of the 2112nt-long human *EGR1* promoter that had originally been cloned into the pGL4.17 vector (−1951/+161 relative to the transcription start site; TSS) ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), and subjected these variants to FGF2-mediated *trans*-activation in a dual-luciferase assay ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Four successive rounds of 3- and/or 5-prime sequence shortening and optimization identified a 402nt-long region (−799/--397 relative to TSS) that is critical for FGF2-mediated *trans*-activation (called D-E element) of the *EGR1* promoter ([Figure 1B--D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The addition of two extra copies of the D-E element into the *EGR1* promoter (hEGR1-D) enhanced its response to FGF2 by approximately 50% ([Figure 1E](#fig1){ref-type="fig"}). We named this construct pKrox24(2xD-E_inD)^Luc^ after KROX24, one of the alternative names of EGR1 ([Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}). The level of pKrox24(2xD-E_inD)^Luc^ FGF2-mediated *trans*-activation in RCS cells peaked at approximately 40 ng/ml FGF2. Treatment of RCS cells with higher doses of FGF2 further elevated ERK activation ([@bib20]), but had a negligible effect on pKrox24(2xD-E_inD)^Luc^ activity ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}), implying that it is unlikely that further development of the pKrox24(2xD-E_inD)^Luc^ promoter sequence would yield a significant increase in trans-activation capacity. In the five different cell types tested, pKrox24(2xD-E_inD)^Luc^ responded to the activation of FGFR signaling following FGF2 addition, as well as to the chemical inhibition of endogenous FGFR signaling ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}).

To eliminate inhibitory elements possibly existing within the pKrox24(2xD-E_inD)^Luc^ promoter, a fully synthetic construct was developed, based on *EGR1* promoter and information gained during the pKrox24 development. A human *EGR1* promoter sequence (−1500/+100 bp relative to TSS) was aligned with the corresponding sequences of pig, cow, rat, mouse and chicken *Egr1*, and analyzed by T-Coffee ([@bib31]) to find conserved elements, and by rVista ([@bib26]) to identify transcription factor binding sites. The identified elements, together with previously discovered sequences ([@bib37]), were mapped onto the *EGR1* promoter and cloned into a pGL4.26 vector containing a minimal promoter and firefly luciferase. The resulting reporter was named pKrox24(MapErk)^Luc^ ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). When compared to pKrox24(2xD-E_inD)^Luc^, pKrox24(MapErk)^Luc^ showed no additional increase in FGF2-mediated *trans*-activation, but possessed a significantly lower basal activity in RCS and 293T cells ([Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}).

Additionally, constructs containing five copies of MapErk or two copies of D-E elements, serving as minimal promoters, were generated with either dTomato or DsRed reporter ([Supplementary file 1C](#SD1-data){ref-type="supplementary-material"}). These reporters responded well to FGF2-mediated *trans*-activation following transfection into RCS cells, shown by immunoblot analyses of dTomato and DsRed expression, and live cell imaging ([Figure 1F,G](#fig1){ref-type="fig"}; [Figure 1---figure supplement 8](#fig1s8){ref-type="fig"}). Expression of the constitutively active FGFR3 mutant K650M ([@bib29]) in RCS cells induced dTomato or DsRed expression, and this expression was reversed by treatment with AZD1480, a chemical inhibitor of FGFR3 ([@bib34]) ([Figure 1H,I](#fig1){ref-type="fig"}; [Figure 1---figure supplement 8C](#fig1s8){ref-type="fig"}).

Protein kinases induce EGR1 protein expression in cells {#s2-2}
-------------------------------------------------------

Next, we investigated whether RTKs other than FGFRs induce EGR1 expression in cells. A total of 37 full-length human wild-type (wt) RTKs were cloned into the pcDNA3.1 vector in frame with a C-terminal V5/6xHis epitope, expressed in 293T cells, and verified by immunoblot ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Site-directed mutagenesis was used to generate the major mutants of each RTK associated with human disease, obtained via surveys of published literature, or selected from the catalogue of mutations associated with human cancers or inherited conditions available from the Sanger Cosmic ([@bib10]) and OMIM databases. As RTKs auto-phosphorylate upon activation ([@bib1]), a phosphorylation-specific RTK antibodies were used to estimate the spontaneous or ligand-induced activation of expressed RTKs ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}; [Supplementary file 1D](#SD1-data){ref-type="supplementary-material"}). A total of 254 wt and mutant RTK variants were prepared this way, expressed in 293T cells, and analyzed for EGR1 induction. The results showed that 30 wt RTKs (81%) and 154 (71%) of their mutants induced EGR1 when expressed in 293T cells ([Figure 4](#fig4){ref-type="fig"}).10.7554/eLife.21536.011Figure 2.RTK cloning and validation (part 1).Full-length human RTK cDNA was cloned into pcDNA3.1 vectors and equipped with a C-terminal V5/His epitope. Mutants were created by site-directed mutagenesis. The RTKs were expressed in 293T cells, and their activation was probed by immunoblot with antibodies that recognize the given RTK only when it is phosphorylated (p) at a specific motif, with exception of phosphorylated DDR1 and DDR2 which were detected with pan-pY antibody. A total of 37 wild-type (WT) RTKs and 241 of their mutants were obtained, including disease-associated loss-of-function and gain-of-function mutants, and experimental kinase-inactive mutants (KD). Treatment with the cognate ligands of DDR1, DDR2, KIT, and VEGFR2 was used for the activation of these RTKs.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.011](10.7554/eLife.21536.011)10.7554/eLife.21536.012Figure 3.RTK cloning and validation (part 2).**DOI:** [http://dx.doi.org/10.7554/eLife.21536.012](10.7554/eLife.21536.012)

Three wt RTKs (FGFR3, TIE, VEGFR1) and 27 mutants induced EGR1 expression but were not found to be phosphorylated ([Figures 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}). This is likely due to the fact that in active RTKs some phosphotyrosines are differentially phosphorylated and thus may not be identified by antibodies designed for specific motifs. The most notable example is FGFR3, as all five active mutants associated with skeletal dysplasia and cancer ([@bib18]; [@bib32]; [@bib4]) induced EGR1, but only K650M FGFR3 was found to be phosphorylated by an antibody recognizing FGFR phosphorylation at Y653/Y654. The pseudokinases lacking catalytic activity (ROR1, ROR2, RYK, ERBB3) were among the RTKs that did not induce EGR1, along with RTKs that did not autophosphorylate after expression in 293T cells (TYRO3, INSRR, ROS1) ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Furthermore, 36 mutants failed to induce EGR1 despite being derived from RTKs that induce EGR1 expression. The majority of these mutants (83%) were kinase-inactive mutants ([Figures 2](#fig2){ref-type="fig"}--[4](#fig4){ref-type="fig"}). The remaining six mutants did not induce EGR1 because of weak activation (DDR1^R896Q^, ERBB4^E836K^, RET^E768N^) or due to an unknown reason (RON^R470C^, RON^R1231C^, PDGFRB^D850N^). Overall, the RTK activation correlated with EGR1 induction in 96% (154 out of 160) of the tested wt and mutant RTKs. Thirteen additional non-receptor tyrosine kinases, serine/threonine kinases C-RAF and B-RAF as well as RAS small GTPase, were subjected to the same analyses ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Taken together, we have demonstrated that, apart from the JAK and MAPKK kinases not evaluated in this study, all of the protein kinase oncogenes recognized to date ([@bib36]) are capable of inducing EGR1 expression in 293T cells.10.7554/eLife.21536.013Figure 4.RTKs induce EGR1 protein expression.(**A**, **B**) Immunoblot analyses of EGR1 induction in 293T cells transfected with wild-type (WT) or mutated RTKs for 24 hr. Cells transfected with empty plasmids serve as the transfection control, and actin serves as the loading control. (**A**) Green, RTK induces EGR1; red, no EGR1 induction by the RTK; \* RTKs that induced EGR1 but were not autophosphorylated ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}); ^¶^ RTKs that were autophosphorylated but did not induce EGR1; ^L^ RTKs activated by the addition of their cognate ligands.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.013](10.7554/eLife.21536.013)10.7554/eLife.21536.014Figure 4---figure supplement 1.EGR1 expression induced by non-receptor tyrosine kinases, serine/threonine kinases C-RAF and B-RAF, and RAS small GTPase.(**A**) Immunoblot validation of cytoplasmic tyrosine kinases (ABL, BCR-ABL, ITK, SYK, TEC, TYK2, ZAP70, BLK, FGR, FYN, YES, LCK, LYN), serine/threonine kinases (B-RAF, C-RAF) and small GTPase RAS expression and activation in 293T cells. Cells transfected with empty plasmid serve as transfection control. Actin serves as the loading control. Control, untransfected cells. WT, wild-type RAS, V12, active RAS mutant. Two variants (p190 and p210) of oncogenic BCR-ABL are shown. CAAX, active C-RAF variant; V600E, oncogenic B-RAF mutant. (**B**) Immunoblot analysis of EGR1 protein induction in 293T cells, following 24 hr of expression of the indicated proteins in 293T cells. (**C**) Compilation of the data generated in (**B**). Green, expression of given protein induces EGR1; red, no EGR1 protein induction; \* kinases that induced EGR1 but were not found autophosphorylated; ^¶^ kinases which did not induce EGR1 but were found autophosphorylated. Data show a representative experiment for three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.014](10.7554/eLife.21536.014)

pKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitors {#s2-3}
---------------------------------------------------------------------------------------------

One application of pKrox24 reporters is the identification of novel targets for clinically used kinase inhibitors, which could help repurpose existing anti-cancer drugs or uncover the molecular mechanisms underlying the side-effects they cause in patients. Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a t(9;22)(q34;q11) translocation that produces a cytoplasmic BCR-ABL fusion protein with constitutive tyrosine kinase activity ([@bib42]). The suppression of BCR-ABL catalytic activity with tyrosine kinase inhibitors (TKI) has greatly improved CML prognosis, effectively turning a once fatal cancer into a manageable chronic disease. Several generations of BCR-ABL TKIs have been developed to improve efficacy and overcome the BCR-ABL resistance to first generation TKIs caused by mutations and gene amplifications ([@bib14]; [@bib5]). However, some TKIs, such as ponatinib, can cause severe toxicity in CML patients and even lead to discontinuation of the therapy ([@bib28]). The reasons why these BCR-ABL TKI side-effects occur are not clear, and in this way, the elucidation of how TKIs affect physiological tyrosine kinase signaling is of major interest to CML research. To identify novel targets, we evaluated the activity of five clinically used BCR-ABL TKIs, that is ponatinib, imatinib, dasatinib, bosutinib and nilotinib, against a panel of 28 wt RTKs. Different TKI concentrations were used to assess the inhibition of BCR-ABL activity as well as cell toxicity ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). [Figure 5A](#fig5){ref-type="fig"} shows that all tested TKIs inhibited RTKs that had already been reported as targets in literature ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}), with exception of LTK and INSR, which were identified as two novel targets for nilotinib ([Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"}).10.7554/eLife.21536.015Figure 5.In-cell RTK activity profiling with BCR-ABL and EGFR inhibitors.(**A**) Activity of BCR-ABL inhibitors ponatinib (*Pona.*), imatinib (*Ima.*), dasatinib (*Dasa.*), bosutinib (*Bosu.*), and nilotinib (*Nilo.*) against 28 wild-type RTKs, evaluated in 293T cells transfected with RTKs and treated with inhibitors for 20--24 hr. The panel compiles data from immunoblot detections of activated RTKs, each treated with inhibitor concentrations derived from the experiments shown in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. Only one concentration is shown for nilotinib due to its cell toxicity at higher concentrations. Asterisks highlight the previously unreported nilotinib targets LTK and INSR ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**B**) Activity profiling of 30 wild-type (wt) RTKs and 116 of their active mutants in the presence of 0.5 µM osimertinib. 293T cells were transfected with RTK vectors together with pKrox24(2xD-E_inD)^Luc^24 hr before osimertinib treatment (for 24 hr). The colors reflect the osimertinib-mediated inhibition of pKrox24(2xD-E_inD)^Luc^*trans*-activation induced by a given RTK, relative to cells untreated with osimertinib. Basal levels of osimetrinib-mediated inhibition of pKrox24(2xD-E_inD)^Luc^ were obtained from cells transfected with empty plasmid and then subtracted from the data. (**C**) 293T cells were transfected with wt LTK or its mutants, and treated with osimertinib (Osi.) for 24 hr. The LTK autophosphorylation (p) reflect LTK activity. Total LTK and actin serve as loading controls. (**D**) Cell-free kinase assays were carried out with recombinant LTK or EGFR and osimertinib added to the kinase reaction. Phosphorylation (p) of a recombinant STAT1 and autophosphorylation was used to detect LTK and EGFR activation, respectively. Samples with omitted ATP serve as negative controls for kinase activity.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.015](10.7554/eLife.21536.015)10.7554/eLife.21536.016Figure 5---figure supplement 1.Analyses of cytotoxicity and kinase activities of BCR-ABL and EGFR inhibitors.(**A**) 293T cells were treated with ponatinib, imatinib, dasatinib, bosutinib, nilotinib and osimertinib for 24 hr and the cell amounts were determined by cell counting. Data represent average from three independent experiments (two biological replicates for each point in every experiment) with indicated SD. 0, cells treated with TKI vehicle DMSO. With exception of dasatinib, the inhibitors did not affect 293T proliferation at the concentration ranges (red lines) used in RTK screening ([Figure 5A](#fig5){ref-type="fig"}). (**B**, **C**) Cells were transfected with human wild-type ABL, and p190 and p210 variants of BCR-ABL, and wild-type human EGFR or its activating mutant T790M, treated with inhibitors for 24 hr and analyzed for activating phosphorylation (p) by immunoblot. Actin and total levels of expressed kinases serve as loading controls. Cells transfected with empty plasmid serve as transfection control. (**D**) Evidence demonstrating that 2 and 5 μM nilotinib inhibits expression of transfected FGFR2, MET and RON. (**E**) Inhibition of LTK and INSR autophosphorylation by nilotinib. (**B**--**E**) Data show a representative experiment for three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.016](10.7554/eLife.21536.016)

Osimertinib (AZD9291) is recently described inhibitor of EGFR catalytic activity, and was approved for clinical use in lung carcinoma in 2015 ([@bib7]; [@bib12]). Osimertinib is a mutant-selective EGFR inhibitor, with 200-fold selectivity for EGFR mutants T790M and L858R over the wt EGFR ([@bib7]; [@bib9]; [@bib17]). Crystallographic studies indicate that osimertinib binds to the outer edge of the EGFR ATP binding pocket through a covalent bond with Cys797 ([@bib41]). Although these data provide no clear explanation for EGFR mutant versus the wt selectivity ([@bib7]; [@bib9]; [@bib17]; [@bib41]), osimertinib is expected to possess a very narrow spectrum of RTK specificity, limited to EGFR and the closely related ERBB2 and ERBB4. We tested this prediction by evaluating osimertinib activity against 30 wt RTKs and 116 of their active mutants with a pKrox24(2xD-E_inD)^Luc^ luciferase assay in 293T cells. We observed inhibitory activity for osimertinib against EGFR, ERBB2 and ERBB4, but not for the other 26 RTKs and 99 mutants ([Figure 5B](#fig5){ref-type="fig"}). However, LTK was an exception, as it appeared to be inhibited by osimertinib in both wt and mutant forms. These included the D535N and L844I mutants, which associate with multiple myeloma and stomach carcinoma ([@bib15]; [@bib22]), respectively, and the W831C and H608Y substitutions found in the Cosmic and VarSome databases. The osimertinib activity was confirmed by suppression of the autophosphorylation of LTK expressed in 293T cells, and by inhibition of LTK-mediated phosphorylation of recombinant STAT1 substrate in cell-free kinase assays ([Figure 5C](#fig5){ref-type="fig"}).

The presented pKrox24 technology enables rapid in-cell profiling of a majority of the known protein kinase oncogenes via simple and versatile reporters based on the activity of a downstream protein kinase signaling target. While the luciferase reporters may be applied to tractable cell models to repurpose existing protein kinase inhibitors, the application of fluorescent pKrox24 reporters to high-throughput screening (HTS) of compound libraries offers a major advantage. Cells can be viewed any time during the screening, and this characteristic of HTS would enable researchers to detect false-positive hits based on the inhibition of dTomato and DsRed expression by cell-toxic compounds through mechanisms unrelated to the target protein kinase. Hence, these reporters could improve the interpretation of HTS screening data by readily eliminating false-positive hits.

Methods {#s3}
=======

Cell culture, transfection and luciferase reporter assay {#s3-1}
--------------------------------------------------------

NIH3T3 cells (RRID:[CVCL_0594](https://scicrunch.org/resolver/CVCL_0594)) and 293 T cells (RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) were obtained from ATCC (Manassas, VA). hiPSC cell line AM13 was generated as described before ([@bib21]). hESC (CCTL14; RRID:[CVCL_C860](https://scicrunch.org/resolver/CVCL_C860)) cells were prepared as described before ([@bib8]). RCS cells (RRID:[CVCL_S122](https://scicrunch.org/resolver/CVCL_S122)), KMS11 (RRID:[CVCL_2989](https://scicrunch.org/resolver/CVCL_2989)) and LP1 (RRID:[CVCL_0012](https://scicrunch.org/resolver/CVCL_0012)) cells were obtained as described before ([@bib19]). All used cell lines were routinely evaluated for mycoplasma contamination using DAPI staining and confocal microscopy, and were mycoplasma free. Cells were propagated in DMEM media, supplemented with 10% FBS and antibiotics (Invitrogen, Carlsbad, CA). hESC and hiPSC cells were propagated in feeder-free conditions. For 293T growth assays, 3 × 10 cells were grown in 24-well tissue culture plates for 1 day, and the cells were treated with inhibitors. After 24 hr the cell numbers were determined by cell counter (Beckman Coulter, Brea, CA). Chemicals were obtained from the following manufacturers: FGF2, SCF, FLT3 ligand, VEGF (RnD Systems, Minneapolis, MN); collagen type 1 (Santa Cruz Biotechnology, Santa Cruz, CA); PD0325901 (Tocris Bioscience, Bristol, UK); ponatinib, imatinib, dasatinib, bosutinib, nilotinib, osimertinib, AZD1480, BGJ398 (Selleckchem, Houston, TX); heparin (Sigma-Aldrich, St. Louis, MO). Cells were transfected either by using FuGENE6 transfection reagent (Roche, Basel, Switzerland), polyethylenimine (Sigma-Aldrich) or electroporation with the Neon Transfection System (Invitrogen). For the luciferase reporter assay, cells were also transfected with a vector expressing firefly luciferase and a vector expressing *Renilla* luciferase under the control of a constant promoter (pRL-TK) at a 3/1 ratio. Luciferase signal was quantified 20--24 hr later using the Luciferase or Dual-Luciferase Reporter Assay (Promega, Madison, WI). Osimertinib screening in 293T cells was carried out with pKrox24(2xD-E)^Luc^only, which was transfected at a 1/3 ratio together with the RTK-expressing vector. The cells were treated with 0.5 µM osimertinib 24 hr after transfection, and luciferase signal was determined 24 hr later.

Plasmid cloning and mutagenesis {#s3-2}
-------------------------------

Vectors (pcDNA3.1) carrying C-terminally V5-tagged RTKs were generated by cloning full-length human RTK cDNA into a pcDNA3.1/V5-His TOPO TA vector (Invitrogen). Site-directed mutagenesis was carried-out according to the manufacturer's protocol (Agilent, Santa Clara, CA). Vectors (pCR3.1) carrying N-terminally FLAG-tagged p190 and p210 variants of BCR-ABL were generated by cloning full-length human BCR-ABL p190 cDNA (source pSG5-P190) and full-length human BCR-ABL p210 cDNA (source Bcr/Abl P210LEF) into a pCR3.1 vector (Invitrogen) containing a PGNQNMDYKDDDDK amino acid coding sequence between BamHI and EcoRI in the multiple cloning site. The source vectors pSG5-P190 (Addgene, Cambridge, MA; plasmid \#31285) and Bcr/Abl P210LEF (plasmid \#38158) were a gift from Nora Heisterkamp ([@bib40]; [@bib23]). Promoter regions of *EGR1*, *EGR2*, *RGS1*, *NR4A2* and *DUSP6* were amplified from hESC genomic DNA by PCR and ligated to a pGL4.17 vector (Promega). All EGR1 promoter fragments of different lengths (hEGR1-B - hEGR1-F) were amplified from hEGR1-A by PCR and inserted into vector pGL4.17. The construct pKrox24(1xD-E_inD)^Luc^ was prepared by inserting the active element D-E, amplified from hEGR1-A by PCR, into the hEGR1-D construct. pKrox24(2xD-E_inD)^Luc^ was obtained by cloning synthetic DNA corresponding to two copies of the active element D-E to KpnI site of the hEGR1-D construct. pKrox24(3xD-D2_inD)^Luc^ was obtained by cloning three copies of the active element D-D2 as a synthetic gene by KpnI into the hEGR1-D construct. pKrox24(MapErk)^Luc^ was prepared by inserting synthetic DNA corresponding to five copies of a designed MapErk sequence (listed in [Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}) into KpnI, HindIII sites of the pGL4.26 vector (Promega). Two copies of synthetic DNA corresponding to element D-E were cloned into HindIII,SalI sites of pDsRed-Express-DrVector (Clontech) to obtain pKrox24(2xD-E)^DsRed^. pKrox24(MapErk)^DsRed^ was prepared by cloning of five copies of designed MapErk sequence into EcoRI,BamHI sites of the pDsRed-Express-Dr vector. pKrox24(2xD-E)^dTomato^ and pKrox24(MapErk)^dTomato^ were generated by swapping of dTomato cDNA from ptdTomato Vector (Clontech) to pCLuc-Basic2 by HindIII,NotI and BamHI,NotI sites, respectively. 2xD-E element was cloned to pCLuc-Basic2 by EcoRI,EcoRV sites, MapErk element was cloned into EcoRI,XhoI sites. [Supplementary file 1C](#SD1-data){ref-type="supplementary-material"} lists all expression vectors used in the study; [Supplementary file 1F](#SD1-data){ref-type="supplementary-material"} lists all PCR primers with marked restriction sites used for plasmid generation.

Immunoblotting {#s3-3}
--------------

Cells were harvested into the sample buffer (125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 5% β-mercaptoethanol, 0.02% bromophenol blue). Samples were resolved by SDS-PAGE, transferred onto a PVDF membrane and visualized by chemiluminiscence (Thermo Scientific, Rockford, IL). [Supplementary file 1D](#SD1-data){ref-type="supplementary-material"} lists the antibodies used in the study. Kinase assays were performed with 200 ng of recombinant EGFR or LTK (SignalChem, Richmond, CA) in 50 µl of kinase buffer (60 mM HEPES pH 7.5, 3 mM MgCl~2~, 3 mM MnCl~2~, 3 µM Na~3~VO~4~, 1.2 mM DTT) in the presence of 10 µM ATP for 60 min at 30°C. Recombinant STAT1 was from Cell Science (Newbury port, MA).

Live cell imaging {#s3-4}
-----------------

Time-lapse microscopy experiments with living cells were conducted using either an automated incubation microscope BioStation CT (Nikon, Tokio, Japan) or a confocal laser-scanning microscope Carl Zeiss LSM 700 (Carl Zeiss, Jena, Germany) equipped with an atmospheric chamber. Phase contrast and fluorescence signal images were automatically acquired every 15 min during a 24 hr time period. Images were then processed and analyzed in either Nikon BioStation CT or Carl Zeiss ZEN 2 software. Phase contrast and fluorescence images were exported into Microsoft Publisher for the preparation of publication figures.
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###### Supplementary tables containing

\(A\) Commercial providers of RTK activity profiling; (B) Nucleotide sequences cloned into the promoterless pGL4.17 vector expressing firefly luciferase; (C) Expression vectors used in the study; (D) Antibodies used in the study; (E) Literature survey of anti-RTK activity of BCR-ABL TKIs; (F) Primers used for reporter construction.
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###### Supplementary file contains numerical data for [Figure 1A,B,C,D and E](#fig1){ref-type="fig"}; [Figure 1---figure supplements 3](#fig1s3){ref-type="fig"}, [4](#fig1s4){ref-type="fig"}, [5A, B](#fig1s5){ref-type="fig"}, [7A and B](#fig1s7){ref-type="fig"}; and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.
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###### Supplementary file contains numerical data for [Figure 5B](#fig5){ref-type="fig"}.
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Decision letter

Davis

Roger J

Reviewing editor

University of Massachusetts Medical School

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"One reporter for in-cell activity profiling of majority of protein kinase oncogenes\" for consideration by *eLife*. Your article has been favorably evaluated by Tony Hunter as the Senior Editor and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors describe an optimized EGR1-based reporter that can be used to measure the activity of many receptor tyrosine kinases. The strength of the system is that activity can be used in living cells and that it is amenable to high throughput screening. It is therefore likely that the reporter will be useful for many investigators.

Essential revisions:

1\) Can the output of different kinases be quantitatively compared using this EGR1-driven reporter?

2\) To what extent do different kinases turn on EGR1? Is it possible to normalize for extent of expression and specific activity of the overexpressed kinase?

3\) FGFR inhibitors only partially block reporter activity caused by FGFR. Is this because of autocrine growth factor production and activation of ERK by another pathway? How does this limit the usefulness of the reporter?

4\) The use of over expression in 293T cells to provide ligand-independent signaling is potentially a problem because the constitutive activity of these ligand-regulated receptors may not reflect their physiological or pathophysiological activity? Thus, while the reporter assay may be useful for identifying inhibitors, one wonders if it may be limited in other regards. This issue deserves some comment.

5\) The authors point to the uncertainty surrounding the clinical toxicity of the BCR-ABL inhibitor ponatinib (subsection "pKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitors", first paragraph) as a potential use for their assay, but do not indicate whether their analysis of ponatinib reveals new targets that might explain the side effects arising from its ability to target other RTKs.

6\) While the authors identify new targets for nilotinib (LTK and INSR), this discovery was made without the EGR1-based reporter. Inclusion of data for an application that utilized the EGR1-based reporter would be an effective way to demonstrate the utility of this system.

10.7554/eLife.21536.024

Author response

Essential revisions:

*1) Can the output of different kinases be quantitatively compared using this EGR1-driven reporter?*

In [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}, we used increasing concentrations of FGF-receptor (FGFR) ligand FGF2 to activate endogenous FGFR signaling in cells, in order to test to what extent the level of Krox24 transactivation correlates with differing levels of activation of endogenous FGFR signaling. We demonstrate that Krox24 transactivation gradually increases with 1-40 ng/ml FGF2, but peaks and plateaus at 40-100 ng/ml of FGF2. This suggests that the Krox24 reporters may have a limited capacity to quantitatively record the differences in RTK activation, especially in RTKs which are strong activators of ERK pathway, such as the FGFRs. In the manuscript revision, we tested the ability of Krox24 reporters to record differences in RTK activation by two experiments: (A) by determining whether different mutants belonging to one RTK transactivate Krox24 differently, corresponding to their known activity; (B) by determining whether the two groups of unrelated wt RTKs, belonging to strong or weak ERK activators, transactivate Krox24 reporters differently. The data presented by [Author response image 1](#fig6){ref-type="fig"} demonstrate that, in both cases, the relative differences in RTK activity can be distinguished by the levels of EGR1 expression and Krox24 reporter transactivation.10.7554/eLife.21536.020Author response image 1.(**A**) 293T cells were transfected with pKrox24 reporters together with empty vector and vectors expressing wild-type (WT) FGFR3 or its activating mutants G380R (associated with achondroplasia) and Y373C (associated with thanatophoric dysplasia). Note the differences in pKrox24 transactivation (upper graphs), and EGR1 induction (lower blot), which correspond to well documented differences in relative activity of the FGFR3 variants (see, for instance Krejci et al., PLoS *ONE*. 2008; 3: e3961), which is as follows: wt FGFR3\<G380R\<Y373C. K508M; kinase-dead FGFR3 mutant. (**B**) 293T cells were transfected with pKrox24 reporters together with empty vector and vectors expressing RTKs known to activate ERK pathway either weakly (INSR, IGF1R) or strongly (*FGFR1*, TRKB). Note the differences in pKrox24 transactivation (upper graphs), and EGR1 induction (lower blot), between strong and weak ERK activating RTKs. (Graphs) Values are averages from four biological replicates (each measured twice) with indicated S.D. Statistically significant differences are highlighted (Student\'s t-test; \*\*\*p\<0.001). The levels of RTK expression were quantified by western blot with V5 antibody (lower blot). Actin serves as the loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.020](10.7554/eLife.21536.020)

We equipped all the RTKs and their mutants cloned for this project with C-terminal V5 epitope for easy monitoring of expression of different RTKs via western blot with single commercial V5 antibody. Experiment comparing the EGR1 induction and Krox24 transactivation by unrelated RTKs belonging to different families is shown by the [Author response image 1](#fig6){ref-type="fig"} above. We demonstrate that equally expressed (as determined by V5 western blot) FGFR1, TRKB, INSR and IGF1R induce different levels of EGR1 expression and Krox24 transactivation, corresponding to their known ability to activate ERK pathway. Using the tools developed here, it is therefore possible to directly compare to what levels the different RTKs activate the common pathways of downstream signal transduction.

*3) FGFR inhibitors only partially block reporter activity caused by FGFR. Is this because of autocrine growth factor production and activation of ERK by another pathway? How does this limit the usefulness of the reporter?*

Manuscript [Figure 1H, I](#fig1){ref-type="fig"} demonstrates rather complete inhibition of Krox24 transactivation, mediated by FGFR3 transfection, with the cell treatment of FGFR inhibitor AZD1480. This is in contrast to data presented by [Figure 1---figure supplement 5B](#fig1s5){ref-type="fig"}, which show only partial AZD1480-mediated inhibition of Krox24 transactivation caused by high endogenous FGFR activity in hESC and hiPSC cells. The data presented elsewhere (Gudernova et al., 2016; Human Molecular Genetics, 25, 9-23), or those on [Author response image 2](#fig7){ref-type="fig"} demonstrate that AZD1480 is a potent FGFR inhibitor, capable of complete suppression of activation of even highly active *FGFR1*-3 mutants. Thus the residual Krox24 activity after AZD1480 treatment, as shown in [Figure 1---figure supplement 5B](#fig1s5){ref-type="fig"}, appears to be caused by ERK activation independent of FGFR signaling. This is no surprise since cultured cells usually have some levels of background ERK activity caused by serum growth factors. This fact could limit the use of Krox24 reporters in situations where the RTK transfection or activation of endogenous RTK signaling induces very little ERK activation on the top of high ERK background, and thus the two sources cannot be clearly distinguished from each other. Our data demonstrate that this is not the case for majority of the RTKs and their mutants tested here, which clearly induce EGR1 or transactivate Krox24 reporters when expressed in cells or endogenously, when activated by their cognate ligands ([Figures 1A](#fig1){ref-type="fig"},[4](#fig4){ref-type="fig"},[5B](#fig5){ref-type="fig"}; [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}, [4](#fig1s4){ref-type="fig"}, [5A](#fig1s5){ref-type="fig"}, [8D](#fig1s8){ref-type="fig"}; [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}; [Author response image 2](#fig7){ref-type="fig"}).10.7554/eLife.21536.021Author response image 2.293T cells were transfected with empty vector or vector carrying the given FGFR variant, and treated with indicated AZD1480 for 24 hours.FGFR activation was determined by detection of FGFR auto-phosphorylation (**p**) at Tyr653/654. Actin serves as the loading control. Control, untransfected cells. Note the efficient inhibition of FGFR activation with AZD1480, even in the case of highly active FGFR2 and FGFR3 mutants N550K and K650M, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.021](10.7554/eLife.21536.021)

In the manuscript, the reporter transactivation data presented by [Figure 1A-G](#fig1){ref-type="fig"} and [Figure 1---figure supplements 4](#fig1s4){ref-type="fig"}, [5A](#fig1s5){ref-type="fig"}, [7](#fig1s7){ref-type="fig"} and [8A, B, D](#fig1s8){ref-type="fig"} were generated by treatment of three different cell types with fibroblast growth factor (FGF)-receptor ligand FGF2, and thus reflect the Krox24 reporter transactivation by endogenous FGFR signaling. In the revised manuscript, we evaluated the capacity of endogenous signaling of two other RTK families, EGFR and TRK, to transactivate Krox24 reporters. [Author response image 3](#fig8){ref-type="fig"} shows induction of EGR1 expression and transactivation of Krox24 reporters, mediated by endogenous EGFR signaling in 293T cells (activated by addition of EGF) or by endogenous TRK signaling in PC12 cells (activated by additions of NGF). Altogether, this demonstrates the capacity of Krox24 reporters to monitor the ligand-dependent activation of endogenous RTK signaling in cells.10.7554/eLife.21536.022Author response image 3.(**A**) 293T cells and (**B**) PC12 cells were transfected with pKrox24 reporters alone (293T) or together (PC12) with vector carrying *Renilla* luciferase under constant promoter (pRL-TK). Cells were treated with EGF (50 ng/ml) or NGF (100 ng/ml) for 24 hours before the level of Krox24 transactivation was determined by luciferase (**A**) or dual-luciferase (**B**) assay. Values are averages from four biological replicates (each measured twice) with indicated S.D. Statistically significant differences are highlighted (Student\'s t-test; \*\*\*p\<0.001). Results are representative for three independent experiments. The levels of EGR1 induction by EGF or NGF treatment were determined by western blot. Actin serves as the loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.21536.022](10.7554/eLife.21536.022)

*2) To what extent do different kinases turn on EGR1? Is it possible to normalize for extent of expression and specific activity of the overexpressed kinase?*

*4) The use of over expression in 293T cells to provide ligand-independent signaling is potentially a problem because the constitutive activity of these ligand-regulated receptors may not reflect their physiological or pathophysiological activity? Thus, while the reporter assay may be useful for identifying inhibitors, one wonders if it may be limited in other regards. This issue deserves some comment.*

*5) The authors point to the uncertainty surrounding the clinical toxicity of the BCR-ABL inhibitor ponatinib (subsection "pKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitors", first paragraph) as a potential use for their assay, but do not indicate whether their analysis of ponatinib reveals new targets that might explain the side effects arising from its ability to target other RTKs.*

All clinically used BCR-ABL TKIs display some toxicity, which in the case of ponatinib resulted in recent discontinuation of the therapy. The analysis presented by manuscript [Figure 5A](#fig5){ref-type="fig"} reveals off-target activities for all five tested BCR-ABL TKIs, in agreement with the published literature ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}). Compared to other TKIs, ponatinib inhibits the largest amount of RTKs, which may account for its side effects in the chronic myeloid leukemia therapy, which exceed those of other TKIs. We however did not discover any novel ponatinib targets, all RTKs found inhibited here were already reported in the literature ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}). Instead, the experiments presented by [Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"} identified two new targets (LTK and INSR) for nilotinib. The revised manuscript text was updated to clearly indicate that, out of the five TKIs tested, novel targets were only identified for nilotinib (subsection "pKrox24 reporters can be used to identify novel targets for clinically used kinase inhibitors", first paragraph).

We have chosen the BCR-ABL TKIs to demonstrate one possible application of the tools developed here because their off-target activities have been thoroughly evaluated before, and thus the published evidence may serve as a reference for estimation of the fidelity of developed screening assays. Our data demonstrate that the off-target activities of all five BCR-ABL TKIs found here match those previously reported, and that novel targets can be found even for the well-studied TKIs.

6\) While the authors identify new targets for nilotinib (LTK and INSR), this discovery was made without the EGR1-based reporter. Inclusion of data for an application that utilized the EGR1-based reporter would be an effective way to demonstrate the utility of this system.

As suggested by published literature ([Supplementary file 1E](#SD1-data){ref-type="supplementary-material"}), nilotinib and other four BCR-ABL TKIs evaluated in the study ([Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) inhibit many RTKs and thus any potential novel targets found in reporter screening would have to be validated and compared with known targets by independent and more precise experimental approach. To preserve time and resources, we therefore opted to skip the initial reporter screening and evaluated the TKI activity in experiments which allow determination of TKI effect on given RTK activity directly and in different TKI concentrations, as presented in [Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}.

The experiments presented by [Figure 5B](#fig5){ref-type="fig"} utilize the EGR1-based reporter to discover LTK as a novel target of EGFR inhibitor osimertinib, demonstrating the utility of Krox24 reporters for finding new targets for RTK inhibitors already used in clinic.
